News Release



Santen Receives Positive Recommendation from CDSCO for Sirolimus

July 4, 2016 – Santen India Private Limited (Bangalore, India) and Santen Pharmaceutical Co., Ltd. (Osaka, Japan) announced today that the Subject Expert Committee (SEC) of the India Central Drugs Standard Control Organization (CDSCO) has issued a positive recommendation for the import and marketing of Sirolimus 22mg/mL intravitreal solution for the chronic treatment of non-infectious uveitis of the posterior segment (NIU-PS) of the eye. Sirolimus, as an intravitreal (IVT) solution for the eye, is a targeted mTOR (mammalian target of rapamycin) inhibitor, which acts on NIU-PS as an immunoregulator by interrupting the inflammatory cascade and promoting immune tolerance. Sirolimus IVT solution is currently being developed globally for NIU-PS.

- END -

About Santen

As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, sales, and marketing of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in over 50 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen's website (www.santen.com).

Santen Forward-looking Statements

Information provided in this press release contains forward-looking statements. The achievement of these forecasts is subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

Contact

Santen India Private Limited No.216, Raheja Chambers 12 Museum Road Bangalore 560001, India Tel: +1-91-80-49323700